Abbvie Inc ABBV

$293.30 +1.99 (0.68%)

Valuation

Market cap
514,924,192,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
22.47
P/E (forward)
20.60
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
5,867,000
Avg volume
4,960,102
Day's range
$289.59 – $294.57
Shares out
1,767,616,000
Stochastic %K
56%
Beta
0.20
Analysts
Moderate Buy
Price target
$305.93

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

HydrogenH2 Nov 10, 11:04 AM
$ABBV Payout is @ 281.66% according to Finviz ...
0 replies
PoseidonCalls Nov 10, 12:06 AM
Short sellers are ruining american small caps and driving companies into bankruptcy!! FMFC has barely 800 watchers on Stocktwits and has been shorted down to only 1.5 million market cap. You could literally buy the ENTIRE company! Webull data stating that FMFC has only 492k shares outstanding and 243k shares float. Watch FMFC here. Making a move 🚀 💎 👀 $ABBV $ABNB
0 replies
55X_ROI_Q1_2026 Nov 9, 10:26 PM
$SLS Phase 3 Results and Share Price Launch -IMMINENT. $MRNA from $25 earlier in the Year to $280 today --- + over $80B in additional Market Value - Based on Phase 3 Registrational Cancer Vaccine Results - SLS is NEXT. P3 results are Imminent for GPs - A revolutionary Immunotherapy to prevent AML Remission and extend survival. While we are seeing Miraculous survival the SLS Phase 3, BAT for Control Patients FAILEDto Increase Survival in 5 recent Clinical trials including 2 AML Remission Trials conducted by $ABBV. And Gps has proven effective in all prior trials, including 2 Separate Phase 2 Trials for AML First and AML Second Remission - with 2x and 4x advantage over BAT. //
1 replies
55X_ROI_Q1_2026 Nov 9, 7:29 PM
$SLS $ABBV Does everyone remember when $ABVX was bumping around from $5 - $10 per share ? and then it T1 Trading Halted when it Announced its P3 Trial Topline Results ? and then Opened UP +600% at $60 Per Share? from $10 to$60 in a heartbeat... and it Kept Climbing to a high of $147 Per Share From $5 to $147 all Based on P3 Trial Results Something very similar is about to Happen HERE> $MRNA just added $80B in Mkt Cap based on its P3 Cancer Vaccine Results.
0 replies
Albino_Trader123 Nov 9, 6:23 PM
$ABBV Still setting up nicely on tight 4 week base. Tried to breakout and flushed it last week. Now trying to reclaim back over the base
0 replies
HydrogenH2 Nov 9, 5:00 PM
$ABT $ABBV Adding to my position slowly !!
0 replies
55X_ROI_Q1_2026 Nov 9, 4:46 PM
$SLS $ABBV Dr. H. Kantarjian, Chair of MD Anderson's Leukemia Dept., and the world's most pre-eminent hematological oncologist, is not only the SLS Phase 3 Trial Global Lead, but as the trial Steering Committee Chair, also helped design the Registrational trial... Results are Imminent.
0 replies
55X_ROI_Q1_2026 Nov 9, 3:22 PM
$SLS $ABVX First Remission (CR1) Median Overall Survival, Absent Transplant BAT/ SOC is Onureg / ORAL AZ - MOS is 24.7 MONTHS* -- Adding Venetoclax to Oral AZ Failed to Increase MOS in 5 Large Trials. -- including Failing 2 Phase 3 Trials, conducted by $ABBV for AML Remission • VIALE-M Failed in First Remission Transplant Ineligible AML • VIALE-T Failed in Post Transplant Maintenance Dr. Kantarjian of MD ANDERSON, Published REAL WORLD Data showing ADDING Venetoclax to Oral AZ for First Remission ACTUALLY LOWERED SURVIVAL in combination - MOS OF JUST 18.6 months vs 24.7. *GPS has proven effective in Preventing Relapse and Extending Survival in ALL Previous Trials INCLUDING In 2 Phase 2 Trials for AML REMISSION PATIENTS Ineligible for Transplant •• With a MOS > 67.6 Months in FIRST REMISSION // 67.6 vs BAT 24.7 • 21 Month MOS in Second Remission / Stat Sig, all MRD+ and Older who got less Gps immunotherapy - just 12 doses in Year 1 vs 15 Y1 doses and extended beyond in the REGAL P3. // //
0 replies